Myofibroblast secretome and its auto-/paracrine signaling

Expert Review of Cardiovascular Therapy

Volumn 14, Issue 5, 2016, Pages 591-598

  Bomb, Ritin ^a   Heckle, Mark R ^a   Sun, Yao ^a   Mancarella, Salvatore ^a   Guntaka, Ramareddy V ^a   Gerling, Ivan C ^a   Weber, Karl T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

angiotensin II; auto paracrine signaling; Cardiac fibrosis; cardioprotection; myofibroblast secretome

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; COLLAGEN TYPE 1; FIBRILLAR COLLAGEN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; COLLAGEN;

APOPTOSIS; ARRHYTHMOGENESIS; AUTOCRINE EFFECT; CARDIAC MUSCLE CELL; CELL DEDIFFERENTIATION; CELL SURVIVAL; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; GENETIC TRANSCRIPTION; HEART MITOCHONDRION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HUMAN; IMMOBILIZED CELL; INNER MEMBRANE; INTRACELLULAR SIGNALING; LIGAND BINDING; MICROFILAMENT; MUSCLE CELL; MYOFIBROBLAST; OXIDATIVE STRESS; PARACRINE SIGNALING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SARCOLEMMA; TISSUE REPAIR; FIBROBLAST; FIBROSIS; METABOLISM; PATHOLOGY; PHYSIOLOGY; WOUND HEALING;

ANGIOTENSIN II; COLLAGEN; FIBROBLASTS; FIBROSIS; HUMANS; MYOFIBROBLASTS; PARACRINE COMMUNICATION; WOUND HEALING;

EID: 84958532091     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2016.1147348     Document Type: Review

References (99)

1. Cotran RS, Kumar V, Robbins SL. The heart. In: Cotran RS, Kumar V, Robbins SL., editors. Robbins pathologic basis of disease. 4th ed. Philadelphia (PA): W B Saunders; 1989. p. 597-656.
2. Pearlman ES, Weber KT, Janicki JS, et al. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest. 1982; 46: 158-164.
3. Beltrami CA, Finato N, Rocco M, et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation. 1994; 89: 151-163.
4. Factor SM, Butany J, Sole MJ, et al. Pathologic fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1991; 17: 1343-1351.
5. Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002; 40: 2156-2164.
6. Matzinger P. The danger model: a renewed sense of self. Science. 2002; 296: 301-305.
7. Sun Y, Zhang J, Zhang JQ, et al. Renin expression at sites of repair in the infarcted rat heart. J Mol Cell Cardiol. 2001; 33: 995-1003.
8. Sun Y, Cleutjens JPM, Diaz-Arias AA, et al. Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat. Cardiovasc Res. 1994; 28: 1423-1432.
9. Sun Y, Weber KT. Cells expressing angiotensin II receptors in fibrous tissue of rat heart. Cardiovasc Res. 1996; 31: 518-525.
10. Sun Y, Zhang JQ, Zhang J, et al. Angiotensin II, transforming growth factor-beta 1 and repair in the infarcted heart. J Mol Cell Cardiol. 1998; 30: 1559-1569.
11. Horiguchi M, Ota M, Rifkin DB. Matrix control of transforming growth factor-β function. J Biochem. 2012; 152: 321-329.
12. Ausma J, Wijffels M, van Eys G, et al. Dedifferentiation of atrial cardiomyocytes as a result of chronic atrial fibrillation. Am J Pathol. 1997; 151: 985-997.
13. Fredj S, Bescond J, Louault C, et al. Interactions between cardiac cells enhance cardiomyocyte hypertrophy and increase fibroblast proliferation. J Cell Physiol. 2005; 202: 891-899.
14. LaFramboise WA, Scalise D, Stoodley P, et al. Cardiac fibroblasts influence cardiomyocyte phenotype in vitro. Am J Physiol Cell Physiol. 2007; 292: C1799-1808.
15. Rücker-Martin C, Pecker F, Godreau D, et al. Dedifferentiation of atrial myocytes during atrial fibrillation: role of fibroblast proliferation in vitro. Cardiovasc Res. 2002; 55: 38-52.
16. Driesen RB, Verheyen FK, Dispersyn GD, et al. Structural adaptation in adult rabbit ventricular myocytes: influence of dynamic physical interaction with fibroblasts. Cell Biochem Biophys. 2006; 44: 119-128.
17. Szibor M, Pöling J, Warnecke H, et al. Remodeling and dedifferentiation of adult cardiomyocytes during disease and regeneration. Cell Mol Life Sci. 2014; 71: 1907-1916.
18. Zaglia T, Dedja A, Candiotto C, et al. Cardiac interstitial cells express GATA4 and control dedifferentiation and cell cycle re-entry of adult cardiomyocytes. J Mol Cell Cardiol. 2009; 46: 653-662.
19. Kamalov G, Zhao W, Zhao T, et al. Atrophic cardiomyocyte signaling in hypertensive heart disease. J Cardiovasc Pharmacol. 2013; 62: 497-506.
20. Al Darazi F, Zhao W, Zhao T, et al. Small dedifferentiated cardiomyocytes bordering on microdomains of fibrosis: evidence for reverse remodeling with assisted recovery. J Cardiovasc Pharmacol. 2014; 64: 237-246.
21. Pol CJ, Muller A, Simonides WS. Cardiomyocyte-specific inactivation of thyroid hormone in pathologic ventricular hypertrophy: an adaptative response or part of the problem? Heart Fail Rev. 2010; 15: 133-142.
22. Wassen FWJS, Schiel AE, Kuiper GGJM, et al. Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure. Endocrinology. 2002; 143: 2812-2815.
23. Pol CJ, Muller A, Zuidwijk MJ, et al. Left-ventricular remodeling after myocardial infarction is associated with a cardiomyocyte-specific hypothyroid condition. Endocrinology. 2011; 152: 669-679.
24. Dixon IMC, Wigle JT. Cardiac fibrosis and heart failure: cause or effect? New York (NY): Springer International; 2015.
25. Thannickal VJ, Zhou Y, Gaggar A, et al. Fibrosis: ultimate and proximate causes. J Clin Invest. 2014; 124: 4673-4677.
26. Neary R, Watson CJ, Baugh JA. Epigenetics and the overhealing wound: the role of DNA methylation in fibrosis. Fibrogenesis Tissue Repair. 2015; 8: 18.
27. Shinde AV, Frangogiannis NG. Fibroblasts in myocardial infarction: a role in inflammation and repair. J Mol Cell Cardiol. 2014; 70: 74-82.
28. Weber KT, Sun Y, Bhattacharya SK, et al. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol. 2013; 10: 15-26.
29. Katwa LC, Tyagi SC, Campbell SE, et al. Valvular interstitial cells express angiotensinogen and cathepsin D, and generate angiotensin peptides. Int J Biochem Cell Biol. 1996; 28: 807-821.
30. Montorfano I, Becerra A, Cerro R, et al. Oxidative stress mediates the conversion of endothelial cells into myofibroblasts via a TGF-β1 and TGF-β2-dependent pathway. Lab Invest. 2014; 94: 1068-1082.
31. Bondi CD, Manickam N, Lee DY, et al. NAD(P)H oxidase mediates TGF-beta1-induced activation of kidney myofibroblasts. J Am Soc Nephrol. 2010; 21: 93-102.
32. Cleutjens JPM, Verluyten MJA, Smits JFM, et al. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol. 1995; 147: 325-338.
33. Whittaker P. Unravelling the mysteries of collagen and cicatrix after myocardial infarction. Cardiovasc Res. 1996; 31: 19-27.
34. Fomovsky GM, Rouillard AD, Holmes JW. Regional mechanics determine collagen fiber structure in healing myocardial infarcts. J Mol Cell Cardiol. 2012; 52: 1083-1090.
35. Sun Y, Kiani MF, Postlethwaite AE, et al. Infarct scar as living tissue. Basic Res Cardiol. 2002; 97: 343-347.
36. van den Borne SWM, Diez J, Blankesteijn WM, et al. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol. 2010; 7: 30-37.
37. Sun Y, Weber KT. Angiotensin-converting enzyme and wound healing in diverse tissues of the rat. J Lab Clin Med. 1996; 127: 94-101.
38. Sun Y, Ramires FJA, Zhou G, et al. Fibrous tissue and angiotensin II. J Mol Cell Cardiol. 1997; 29: 2001-2012.
39. Katwa LC, Sun Y, Campbell SE, et al. Pouch tissue and angiotensin peptide generation. J Mol Cell Cardiol. 1998; 30: 1401-1413.
40. Sun Y, Zhang J, Lu L, et al. Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart. J Lab Clin Med. 2004; 143: 41-51.
41. Sun Y, Weber KT. Angiotensin II and aldosterone receptor binding in rat heart and kidney: response to chronic angiotensin II or aldosterone administration. J Lab Clin Med. 1993; 122: 404-411.
42. Katwa LC, Campbell SE, Tyagi SC, et al. Cultured myofibroblasts generate angiotensin peptides de novo. J Mol Cell Cardiol. 1997; 29: 1375-1386.
43. Ou R, Sun Y, Ganjam VK, et al. In situ production of angiotensin II by fibrosed rat pericardium. J Mol Cell Cardiol. 1996; 28: 1319-1327.
44. Willems IEMG, Havenith MG, De Mey JGR, et al. The α-smooth muscle actin-positive cells in healing human myocardial scars. Am J Pathol. 1994; 145: 868-875.
45. Sorescu D, Griendling KK. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail. 2002; 8: 132-140.
46. Jiang F, Liu GS, Dusting GJ, et al. NADPH oxidase-dependent redox signaling in TGF-β-mediated fibrotic responses. Redox Biol. 2014; 2: 267-272.
47. Philip JL, Razzaque MA, Han M, et al. Regulation of mitochondrial oxidative stress by β-arrestins in cardiac fibroblasts. Dis Model Mech. 2015; 8: 1579-1589.
48. Follonier Castella L, Gabbiani G, McCulloch CA, et al. Regulation of myofibroblast activities: calcium pulls some strings behind the scene. Exp Cell Res. 2010; 316: 2390-2401.
49. 1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol. 1997; 29: 1947-1958.
50. Wang Q, Usinger W, Nichols B, et al. Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis Tissue Repair. 2011; 4: 4.
51. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008; 214: 199-210.
52. Roche PL, Filomeno KL, Bagchi RA, et al. Intracellular signaling of cardiac fibroblasts. Compr Physiol. 2015; 5: 721-760.
53. Zeglinski MR, Roche P, Hnatowich M, et al. TGFβ1 regulates scleraxis expression in primary cardiac myofibroblasts by a Smad-independent mechanism. Am J Physiol Heart Circ Physiol. 2016;310:H239-H249. ajpheart 00584 02015.
54. Ye H, Cai PC, Zhou Q, et al. Transforming growth factor-β1 suppresses the up-regulation of matrix metalloproteinase-2 by lung fibroblasts in response to tumor necrosis factor-α. Wound Repair Regen. 2011; 19: 392-399.
55. Swynghedauw B. Molecular cardiology for the cardiologist. Boston (MA): Kluwer; 1995.
56. Campbell SE, Rakusan K, Gerdes AM. Change in cardiac myocyte size distribution in aortic-constricted neonatal rats. Basic Res Cardiol. 1989; 84: 247-258.
57. Jalil JE, Janicki JS, Pick R, et al. Fibrosis-induced reduction of endomyocardium in the rat after isoproterenol treatment. Circ Res. 1989; 65: 258-264.
58. Touyz RM, Sventek P, Lariviére R, et al. Cytosolic calcium changes induced by angiotensin II in neonatal rat atrial and ventricular cardiomyocytes are mediated via angiotensin II subtype 1 receptors. Hypertension. 1996; 27: 1090-1096.
59. Pandya K, Kim HS, Smithies O. Fibrosis, not cell size, delineates β-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo. Proc Natl Acad Sci USA. 2006; 103: 16864-16869.
60. López JE, Myagmar BE, Swigart PM, et al. β-myosin heavy chain is induced by pressure overload in a minor subpopulation of smaller mouse cardiac myocytes. Circ Res. 2011; 109: 629-638.
61. Sukhanov S, Semprun-Prieto L, Yoshida T, et al. Angiotensin II, oxidative stress and skeletal muscle wasting. Am J Med Sci. 2011; 342: 143-147.
62. Weber KT, Jalil JE, Janicki JS, et al. Myocardial collagen remodeling in pressure overload hypertrophy: a case for interstitial heart disease. Am J Hypertens. 1989; 2: 931-940.
63. Collier P, Ledwidge M, McDonald K. Diagnostics and therapeutic interventions in myocardial interstitial disease, a previously neglected pathology. QJM. 2012; 105: 721-724.
64. Griffiths EJ. Mitochondria and heart disease. Adv Exp Med Biol. 2012; 942: 249-267.
65. Dai DF, Chen T, Szeto H, et al. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol. 2011; 58: 73-82.
66. Asemu G, OConnell KA, Cox JW, et al. Enhanced resistance to permeability transition in interfibrillar cardiac mitochondria in dogs: effects of aging and long-term aldosterone infusion. Am J Physiol Heart Circ Physiol. 2013; 304: H514-528.
67. Shahbaz AU, Kamalov G, Zhao W, et al. Mitochondria-targeted cardioprotection in aldosteronism. J Cardiovasc Pharmacol. 2011; 57: 37-43.
68. Cheema Y, Sherrod JN, Zhao W, et al. Mitochondriocentric pathway to cardiomyocyte necrosis in aldosteronism: cardioprotective responses to carvedilol and nebivolol. J Cardiovasc Pharmacol. 2011; 58: 80-86.
69. ATP channels and permeability transition pores of mitochondria in dogs. Cardiovasc Drugs Ther. 2012; 26: 217-226.
70. 2+ overload and cell death. J Clin Invest. 2012; 122: 1222-1232.
71. Bauersachs J. Regulation of myocardial fibrosis by MicroRNAs. J Cardiovasc Pharmacol. 2010; 56: 454-459.
72. Thum T, Lorenzen JM. Cardiac fibrosis revisited by microRNA therapeutics. Circulation. 2012; 126: 800-802.
73. Gieling RG, Burt AD, Mann DA. Fibrosis and cirrhosis reversibility-molecular mechanisms. Clin Liver Dis. 2008; 12: 915-937.
74. Robinson CM, Watson CJ, Baugh JA. Epigenetics within the matrix: a neo-regulator of fibrotic disease. Epigenetics. 2012; 7: 987-993.
75. Watson CJ, Horgan S, Neary R, et al. Epigenetic therapy for the treatment of hypertension-induced cardiac hypertrophy and fibrosis. J Cardiovasc Pharmacol Ther. 2016;21:127-137.
76. Smits JFM, van Krimpen C, Schoemaker RG, et al. Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol. 1992; 20: 772-778.
77. Tsutsui H, Matsushima S, Kinugawa S, et al. Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Hypertens Res. 2007; 30: 439-449.
78. Matsusaka H, Kinugawa S, Ide T, et al. Angiotensin II type 1 receptor blocker attenuates exacerbated left ventricular remodeling and failure in diabetes-associated myocardial infarction. J Cardiovasc Pharmacol. 2006; 48: 95-102.
79. Iwamoto M, Hirohata S, Ogawa H, et al. Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan. Hypertens Res. 2010; 33: 1305-1311.
80. Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol. 2005; 90: 449-455.
81. Fujiwara Y, Shiraya S, Miyake T, et al. Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan. Int J Mol Med. 2008; 22: 703-708.
82. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006; 312: 117-121.
83. Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: from angiotensin I to angiotensin (1-7). Cardiovasc Res. 2007; 73: 463-469.
84. Zisman LS, Keller RS, Weaver B, et al. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation. 2003; 108: 1707-1712.
85. Burrell LM, Risvanis J, Kubota E, et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 2005; 26: 369-375; discussion 322-364.
86. Takeda Y, Zhu A, Yoneda T, et al. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats. Am J Hypertens. 2007; 20: 1119-1124.
87. Sukumaran V, Veeraveedu PT, Gurusamy N, et al. Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis. Int J Biol Sci. 2011; 7: 1077-1092.
88. Kassiri Z, Zhong J, Guo D, et al. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail. 2009; 2: 446-455.
89. Zhao YX, Yin HQ, Yu QT, et al. ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction. Hum Gene Ther. 2010; 21: 1545-1554.
90. Dong B, Yu QT, Dai HY, et al. Angiotensin-converting enzyme-2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy. J Am Coll Cardiol. 2012; 59: 739-747.
91. Trask AJ, Groban L, Westwood BM, et al. Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats. Am J Hypertens. 2010; 23: 687-693.
92. Yang F, Chung ACK, Huang XR, et al. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-β-dependent and-independent Smad pathways: the role of Smad3. Hypertension. 2009; 54: 877-884.
93. Hinz B, Phan SH, Thannickal VJ, et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol. 2012; 180: 1340-1355.
94. Guntaka RV, Varma BR, Weber KT. Triplex-forming oligonucleotides as modulators of gene expression. Int J Biochem Cell Biol. 2003; 35: 22-31.
95. Koilan S, Hamilton D, Baburyan N, et al. Prevention of liver fibrosis by triple helix-forming oligodeoxyribonucleotides targeted to the promoter region of type I collagen gene. Oligonucleotides. 2010; 20: 231-237.
96. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation. 1991; 83: 1771-1779.
97. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000; 102: 1388-1393.
98. 1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension. 2000; 35: 1197-1202.
99. Díez J, Querejeta R, López B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002; 105: 2512-2517.